Abstract
The current clinical trial presents a review of CKD-patients enrolled for Autologous Adipose-Derived Mesenchymal Stem Cells (adMSCs) transplantation at Bangladesh Laser & Cell Surgery (BLCS) Institute & Hospital. Between April 2019 to June 2021, 52 CKD-patients were enrolled in this phase 1 & 2 trial receiving intravenous autologous adMSCs transplantation. Twenty-three CKD-patients who had received MSCs transplantation and had also followed-up with di-ethylene tri-amine Penta-acetic acid (DTPA) -based glomerular filtration rate (GFR) assessment, were considered for analysis. The mean (SD) DTPA-based GFR was significantly improved after adMSCs transplantation among study participants than the baseline mean (SD) DTPA-based GFR (19.79 [12.4] vs 15.07 [11.4], p=0.003). The DTPA-based GFR improved in stage-5 CKD patients with and without dialysis after MSCs transplantation, but a significant mean difference was observed only in CKD patients on dialysis (7.1 [6.9] vs 14.2 [12.6], p=0.011). Hence, pre-dialysis patients DTPA-GFR both at baseline and endline was higher than patients those on dialysis. The obtained results revealed that renal function improves in CKD patients through MSCs transplantation. No significant side effects or complication pertaining specifically to stem cell transplantation was observed during the study period.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
